Your browser doesn't support javascript.
loading
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Liu, J F; Barry, W T; Birrer, M; Lee, J-M; Buckanovich, R J; Fleming, G F; Rimel, B J; Buss, M K; Nattam, S R; Hurteau, J; Luo, W; Curtis, J; Whalen, C; Kohn, E C; Ivy, S P; Matulonis, U A.
Affiliation
  • Liu JF; Division of Gynecologic Oncology, Department of Medical Oncology. Electronic address: joyce_liu@dfci.harvard.edu.
  • Barry WT; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston.
  • Birrer M; Department of Medical Oncology, Massachusetts General Hospital, Boston.
  • Lee JM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda.
  • Buckanovich RJ; Department of Internal Medicine, University of Pittsburgh Hillman Cancer Center, Pittsburgh.
  • Fleming GF; Section of Hematology/Oncology, University of Chicago, Chicago.
  • Rimel BJ; Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles.
  • Buss MK; Division of Hematology/Oncology, Beth-Israel Deaconess Medical Center, Boston.
  • Nattam SR; Department of Oncology, Fort Wayne Medical Oncology and Hematology, Fort Wayne.
  • Hurteau J; Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston Hospital, Evanston.
  • Luo W; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston.
  • Curtis J; Division of Gynecologic Oncology, Department of Medical Oncology.
  • Whalen C; Division of Gynecologic Oncology, Department of Medical Oncology.
  • Kohn EC; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA.
  • Ivy SP; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA.
  • Matulonis UA; Division of Gynecologic Oncology, Department of Medical Oncology.
Ann Oncol ; 30(4): 551-557, 2019 04 01.
Article in En | MEDLINE | ID: mdl-30753272
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Phthalazines / Piperazines / Quinazolines / Antineoplastic Combined Chemotherapy Protocols / Neoplasm Recurrence, Local Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Phthalazines / Piperazines / Quinazolines / Antineoplastic Combined Chemotherapy Protocols / Neoplasm Recurrence, Local Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article